Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-PSMA PET/CT in High Risk Prostate Cancer
NCT04614363Phase 2Completed
- Sponsor
- Houston Methodist Research Institute
- Start
- Oct 2020
- Primary completion
- Feb 2022
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gallium ga-68 gozetotide in prostate cancer (PCa), sponsored by Houston Methodist Research Institute. Primary endpoints: Proportion of Patients With Lymph Node Involvement at 18 months and Proportion of Patients Which Clinical Management Was Altered at 18 months. Started Oct 2020; status: completed.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04614363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04614363.